Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Ugeskr Laeger ; 177(39): V03150284, 2015 Sep 21.
Article in Danish | MEDLINE | ID: mdl-26418640

ABSTRACT

The median arcuate ligament syndrome is a rare entity and poorly described in Danish literature. The syndrome is a diagnosis of exclusion and is characterized by chronic abdominal pain, postprandial pain and weight loss. It is believed that the median arcuate ligament, being a fibrous structure of diaphragm, compresses the coeliac trunk thus causing stenosis and malperfusion of the gastrointestinal organs. Until recently, there has been some reluctance to consider intervention with revascularization or ligament release. Within the latest decade minimally invasive techniques, including laparoscopic release of the median arcuate ligament, have shown promising results.


Subject(s)
Median Arcuate Ligament Syndrome/diagnosis , Angiography , Humans , Median Arcuate Ligament Syndrome/diagnostic imaging , Median Arcuate Ligament Syndrome/physiopathology , Median Arcuate Ligament Syndrome/surgery , Ultrasonography
2.
J Diabetes Complications ; 28(4): 517-22, 2014.
Article in English | MEDLINE | ID: mdl-24685364

ABSTRACT

AIM: To investigate whether Roux-en-Y gastric bypass surgery (RYGB) - an in vivo model for normalisation of hyperglycaemia - improves carotid intima-media thickness (IMT) in patients with type 2 diabetes (T2D)/impaired glucose tolerance (IGT) and normal glucose tolerance (NGT). METHODS: Observational prospective study, 34 obese patients (T2D (n = 14)/IGT (n = 4), and NGT (n = 16)) were investigated before and six and 12months after RYGB. RESULTS: Mean carotid IMT was significantly reduced 12months after RYGB in patients with T2D/IGT (-0.041 mm (95% CI -0.069; -0.012, p = 0.005)) but not in patients with NGT (-0.010 mm (-0.039; 0.020, p = 0.52)). The between-group difference was not significant (p=0.13). Twelve months after RYGB, patients with respectively T2D/IGT and NGT demonstrated changes in weight: -29.9 kg, p<0.001/-30.6 kg, p < 0.001, HbA1c: -0.7%, p < 0.001/-0.1%, p = 0.33, systolic blood pressure: -2 mmHg, p = 0.68/-10 mmHg, p = 0.01 and diastolic blood pressure: -8 mmHg, p = 0.003/-11 mmHg, p < 0.001. 80% of T2D patients terminated antihyperglycaemic medication. CONCLUSION: Mean carotid IMT was significantly reduced 12months after RYGB in patients with T2D/IGT which provides evidence to support that the earliest atherosclerotic changes in the arterial wall are reversible. Although numerically different from the changes observed in patients with NGT, the between-group difference was not statistically significant.


Subject(s)
Carotid Intima-Media Thickness , Diabetes Mellitus, Type 2/complications , Diabetic Angiopathies/prevention & control , Down-Regulation , Gastric Bypass , Glucose Intolerance/complications , Obesity, Morbid/surgery , Adolescent , Adult , Body Mass Index , Denmark/epidemiology , Diabetes Mellitus, Type 2/blood , Diabetic Angiopathies/complications , Diabetic Angiopathies/diagnostic imaging , Diabetic Angiopathies/epidemiology , Female , Glucose Intolerance/blood , Glycated Hemoglobin/analysis , Humans , Hyperglycemia/prevention & control , Hypertension/complications , Hypertension/epidemiology , Hypertension/prevention & control , Male , Middle Aged , Obesity, Morbid/blood , Obesity, Morbid/complications , Risk Factors , Vascular Diseases/complications , Vascular Diseases/diagnostic imaging , Vascular Diseases/epidemiology , Vascular Diseases/prevention & control , Weight Loss , Young Adult
3.
Obes Res Clin Pract ; 7(4): e269-74, 2013.
Article in English | MEDLINE | ID: mdl-24306154

ABSTRACT

Experience with Roux-en-Y gastric bypass in patients with type 1 diabetes is very limited, despite an increasing prevalence of obesity also in this population. We describe changes in anthropometric measures, insulin dose, HbA1c, blood pressure, lipid status, and metabolic response to a liquid mixed meal throughout the first year after RYGB in an obese patient with type 1 diabetes. No change in HbA1c was observed, but a 48% reduction in weight-adjusted insulin dose and improvements in cardiovascular risk factors was seen 1 year after surgery. Exaggerated secretions of anorexigenic gut hormones were seen during the meals.


Subject(s)
Cardiovascular Diseases/prevention & control , Diabetes Mellitus, Type 1/surgery , Gastric Bypass , Insulin-Secreting Cells/cytology , Insulin/administration & dosage , Obesity, Morbid/surgery , Adult , Diabetes Mellitus, Type 1/blood , Female , Humans , Insulin/blood , Obesity, Morbid/blood , Risk Factors
4.
Diabetes Care ; 33(2): 375-7, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19918005

ABSTRACT

OBJECTIVE: To examine after gastric bypass the effect of peroral versus gastroduodenal feeding on glucose metabolism. RESEARCH DESIGN AND METHODS: A type 2 diabetic patient was examined on 2 consecutive days 5 weeks after gastric bypass. A standard liquid meal was given on the first day into the bypassed gastric remnant and on the second day perorally. Plasma glucose, insulin, C-peptide, glucagon, incretin hormones, peptide YY, and free fatty acids were measured. RESULTS: Peroral feeding reduced 2-h postprandial plasma glucose (7.8 vs. 11.1 mmol/l) and incremental area under the glucose curve (iAUC) (0.33 vs. 0.49 mmol . l(-1) . min(-1)) compared with gastroduodenal feeding. beta-Cell function (iAUC(Cpeptide/Glu)) was more than twofold improved during peroral feeding, and the glucagon-like peptide (GLP)-1 response increased nearly fivefold. CONCLUSIONS: Improvement in postprandial glucose metabolism after gastric bypass is an immediate and direct consequence of the gastrointestinal rearrangement, associated with exaggerated GLP-1 release and independent of changes in insulin sensitivity, weight loss, and caloric restriction.


Subject(s)
Blood Glucose/metabolism , Enteral Nutrition , Gastric Bypass , Glucagon-Like Peptide 1/metabolism , Obesity, Morbid/surgery , Postoperative Period , Postprandial Period/physiology , Area Under Curve , C-Peptide/blood , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/surgery , Fatty Acids, Nonesterified/blood , Glucagon/blood , Glucagon-Like Peptide 1/blood , Humans , Incretins/blood , Male , Middle Aged , Peptide YY/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...